S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   298.90 (+0.88%)
AAPL   116.50 (+0.41%)
MSFT   215.19 (+0.62%)
FB   277.66 (+0.75%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,197.04 (+0.38%)
TSLA   585.65 (+2.03%)
NVDA   530.10 (+0.13%)
BABA   276.76 (-0.35%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.18 (+0.54%)
T   29.03 (+0.14%)
NIO   54.16 (+0.88%)
F   9.10 (+0.22%)
ACB   10.41 (+19.52%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   298.90 (+0.88%)
AAPL   116.50 (+0.41%)
MSFT   215.19 (+0.62%)
FB   277.66 (+0.75%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,197.04 (+0.38%)
TSLA   585.65 (+2.03%)
NVDA   530.10 (+0.13%)
BABA   276.76 (-0.35%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.18 (+0.54%)
T   29.03 (+0.14%)
NIO   54.16 (+0.88%)
F   9.10 (+0.22%)
ACB   10.41 (+19.52%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   298.90 (+0.88%)
AAPL   116.50 (+0.41%)
MSFT   215.19 (+0.62%)
FB   277.66 (+0.75%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,197.04 (+0.38%)
TSLA   585.65 (+2.03%)
NVDA   530.10 (+0.13%)
BABA   276.76 (-0.35%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.18 (+0.54%)
T   29.03 (+0.14%)
NIO   54.16 (+0.88%)
F   9.10 (+0.22%)
ACB   10.41 (+19.52%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   298.90 (+0.88%)
AAPL   116.50 (+0.41%)
MSFT   215.19 (+0.62%)
FB   277.66 (+0.75%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,197.04 (+0.38%)
TSLA   585.65 (+2.03%)
NVDA   530.10 (+0.13%)
BABA   276.76 (-0.35%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.18 (+0.54%)
T   29.03 (+0.14%)
NIO   54.16 (+0.88%)
F   9.10 (+0.22%)
ACB   10.41 (+19.52%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
Log in
NASDAQ:INGN

Inogen Stock Forecast, Price & News

$36.75
+0.65 (+1.80 %)
(As of 11/27/2020 12:56 PM ET)
Add
Compare
Today's Range
$35.66
Now: $36.75
$36.75
50-Day Range
$27.19
MA: $31.13
$37.27
52-Week Range
$26.57
Now: $36.75
$76.89
Volume1,402 shs
Average Volume332,008 shs
Market Capitalization$812.84 million
P/E RatioN/A
Dividend YieldN/A
Beta0.9
Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.
Read More
Inogen logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.9Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars


Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INGN
CUSIPN/A
Phone805-562-0500
Employees1,020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$361.94 million
Cash Flow$2.10 per share
Book Value$15.67 per share

Profitability

Net Income$20.95 million

Miscellaneous

Market Cap$812.84 million
Next Earnings Date2/23/2021 (Estimated)
OptionableOptionable
$36.75
+0.65 (+1.80 %)
(As of 11/27/2020 12:56 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INGN News and Ratings via Email

Sign-up to receive the latest news and ratings for INGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Inogen (NASDAQ:INGN) Frequently Asked Questions

How has Inogen's stock been impacted by COVID-19?

Inogen's stock was trading at $40.61 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, INGN shares have decreased by 9.5% and is now trading at $36.75.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Inogen?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 sell rating and 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Inogen
.

What stocks does MarketBeat like better than Inogen?

Wall Street analysts have given Inogen a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Inogen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Inogen's next earnings date?

Inogen is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Inogen
.

How were Inogen's earnings last quarter?

Inogen, Inc. (NASDAQ:INGN) released its quarterly earnings data on Wednesday, November, 4th. The medical technology company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.02) by $0.06. The medical technology company had revenue of $74.30 million for the quarter, compared to analysts' expectations of $76.06 million. Inogen had a positive return on equity of 0.21% and a negative net margin of 0.66%. The company's quarterly revenue was down 19.1% compared to the same quarter last year. During the same period in the previous year, the company earned $0.31 earnings per share.
View Inogen's earnings history
.

What price target have analysts set for INGN?

4 equities research analysts have issued 1-year target prices for Inogen's stock. Their forecasts range from $35.00 to $75.00. On average, they anticipate Inogen's share price to reach $51.67 in the next year. This suggests a possible upside of 40.6% from the stock's current price.
View analysts' price targets for Inogen
.

Who are some of Inogen's key competitors?

What other stocks do shareholders of Inogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX).

Who are Inogen's key executives?

Inogen's management team includes the following people:
  • Mr. Scott Wilkinson, CEO, Pres & Director (Age 55, Pay $520.62k)
  • Mr. Brenton Taylor, Co-founder & Exec. VP of Engineering (Age 39, Pay $325.88k)
  • Ms. Alison Perry Bauerlein, Co-founder, Exec. VP of Fin., CFO, Corp. Sec. & Corp. Treasurer (Age 39, Pay $371.06k)
  • Mr. Byron Myers, Founder & Exec. VP of Marketing (Age 41, Pay $356.95k)
  • Mr. Bart Sanford, Exec. VP of Operations (Age 54, Pay $372.87k)
  • Mr. Matthew James Bacso C.F.A., CFA, Investor Relations & Corp. Devel. Mang.
  • Mr. Arron Retterer, Exec. VP of Sales
  • Mr. Matthew Pigeon, Investor Relations Officer

What is Inogen's stock symbol?

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Who are Inogen's major shareholders?

Inogen's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.67%), State Street Corp (3.84%), Riverbridge Partners LLC (1.15%), Arrowstreet Capital Limited Partnership (1.10%), Federated Hermes Inc. (0.86%) and Principal Financial Group Inc. (0.61%). Company insiders that own Inogen stock include Heath Lukatch, Loren L Mcfarland and Raymond Huggenberger.
View institutional ownership trends for Inogen
.

Which institutional investors are selling Inogen stock?

INGN stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., JPMorgan Chase & Co., Morgan Stanley, Beacon Investment Advisory Services Inc., Chicago Capital LLC, Riverbridge Partners LLC, Principal Financial Group Inc., and AQR Capital Management LLC.
View insider buying and selling activity for Inogen
.

Which institutional investors are buying Inogen stock?

INGN stock was acquired by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, State Street Corp, Great West Life Assurance Co. Can, Federated Hermes Inc., BlackRock Inc., Voloridge Investment Management LLC, Cubist Systematic Strategies LLC, and Factorial Partners LLC. Company insiders that have bought Inogen stock in the last two years include Heath Lukatch, and Loren L Mcfarland.
View insider buying and selling activity for Inogen
.

How do I buy shares of Inogen?

Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Inogen's stock price today?

One share of INGN stock can currently be purchased for approximately $36.75.

How big of a company is Inogen?

Inogen has a market capitalization of $812.84 million and generates $361.94 million in revenue each year. The medical technology company earns $20.95 million in net income (profit) each year or $1.07 on an earnings per share basis. Inogen employs 1,020 workers across the globe.

What is Inogen's official website?

The official website for Inogen is www.inogen.com.

How can I contact Inogen?

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]

This page was last updated on 11/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.